340B Advocacy Alliance Bulletin
HRSA seeks input on 340B Rebate Model.
The AHA today issued a statement denouncing unprecedented actions taken by Eli Lilly to deny 340B Drug Pricing Program discounts to certain 340B hospitals that do not meet its unilateral data requirements.
HRSA seeks input on 340B Rebate Model.
Eli Lilly Moves to Deny 340B Pricing Over Data Requirements; AHA Urges Federal Action
Memo provides details of new CVS 340B contract pharmacy amendment — please share the memo with your legal team
DEADLINE EXTENDED: Complete 340B survey by June 5.
REMINDER: AHA seeks hospital input on scope of drug company 340B data policy compliance by May 26 deadline.
Complete AHA Survey by May 28 on Drug Company 340B Data Policy Compliance
AHA urges Lilly to drop 340B claims-data policy, proposes neutral clearinghouse.
AHA pushes back on WSJ anti-340B editorial.